Forbes.com / Biotech, Biomedical
Domain overview in Biotech, Biomedical niche. Based on relevant links and pages only.
| forbes.com rank 381 |
| Number of domains linking to forbes.com 26 | semantic flow 1.55 |
| Number of links to forbes.com 31 | semantic flow 1.55 |
| Number of domains linked from forbes.com 11 | semantic flow 0.39 |
| Number of links from forbes.com 11 | semantic flow 0.39 |
Popular pages pointing to forbes.com
Pages with highest topical PageRank pointing to domain.
Popular pages from forbes.com
On-topic pages from domain with highest topical PageRank.
| title / url |  | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| Clovis, Incyte And BioMarin Are Todd Hagopian's Top Takeover Candidates https://www.forbes.com/sites/kenkam/2018/01/24/clovis-incyte-and-biomarin-are-todd-hagopia  | 0.21 | 1 | 8 | 3 | 0 | 0 | 0 | 0 | |
| Wait, It Costs How Much? Biotech Balances Optimism, Uncertainty For 2018 https://www.forbes.com/sites/matthewherper/2018/01/11/wait-it-costs-how-much-biotech-balan | 0.21 | 1 | 5 | 4 | 0 | 0 | 0 | 0 | |
| Celgene Buys Juno Therapeutics: A Risky $9B Bet https://www.forbes.com/sites/johannabennett/2018/01/22/celgene-buys-juno-therapeutics-a-ri | 0.21 | 0.99 | 10 | 7 | 2 | 2 | 0 | 0 | |
| Celgene's $7 Billion Purchase Is Great For Drug Inventors. Is It Great For Celgene? https://www.forbes.com/sites/matthewherper/2018/01/08/celgenes-7-billion-purchase-is-great | 0.19 | 0.99 | 8 | 5 | 0 | 0 | 0 | 0 | |
| Gilead-Kite: A Breakthrough. A $12 Billion Deal. Another Expensive Drug https://www.forbes.com/sites/matthewherper/2017/08/28/gilead-kite-a-breakthrough-a-12-bill | 0.19 | 0.93 | 6 | 5 | 1 | 1 | 0 | 0 |
Domains with most semantic flow to forbes.com
Relevant domains with most links to selected domain.
Domains with most semantic flow from forbes.com
Relevant domains with most links from selected domain.
Most linked pages from forbes.com
Pages from domain with most relevant inbound links.
| url | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| http://www.forbes.com/sites/kenkam/2018/01/24/clovis-incyte-and-biomarin-are-todd-hagopian | 1 | 0.28 | 0.98 | 0.1 | -1 | - | -1 | -1 | -1 | -1 | 0 | 0 | |
| https://www.forbes.com/sites/matthewherper/2018/01/11/wait-it-costs-how-much-biotech-balan | 1 | 0.21 | 0.99 | 0.07 | 1 | yes | 5 | 4 | 0 | 0 | 0 | 0 | |
| https://www.forbes.com/sites/johannabennett/2018/01/22/celgene-buys-juno-therapeutics-a-ri | 1 | 0.21 | 0.98 | 0.07 | 0.99 | yes | 10 | 7 | 2 | 2 | 0 | 0 | |
| http://www.forbes.com/pictures/gihk45ge/the-countrys-biggest-biotechs/ | 1 | 0.17 | 0.97 | 0.07 | -1 | - | -1 | -1 | -1 | -1 | 1 | 1 | |
| https://www.forbes.com/sites/kenkam/2018/01/24/clovis-incyte-and-biomarin-are-todd-hagopia | 1 | 0.21 | 0.95 | 0.07 | 1 | yes | 8 | 3 | 0 | 0 | 0 | 0 | |
| https://www.forbes.com/search/?substream=hashtags&q=Biotech | 1 | 0.18 | 0.99 | 0.06 | -1 | - | -1 | -1 | -1 | -1 | 0 | 0 | |
| https://www.forbes.com/healthcare/ | 1 | 0.18 | 0.01 | 0.06 | 0.57 | yes | 0 | 0 | -1 | -1 | 0 | 0 | |
| https://www.forbes.com/sites/matthewherper/2012/02/10/the-truly-staggering-cost-of-inventi | 1 | 0.16 | 0.86 | 0.06 | 0.98 | yes | 13 | 6 | 1 | 1 | 1 | 1 | |
| https://www.forbes.com/tips/ | 1 | 0.18 | 0.91 | 0.05 | -1 | no | -1 | -1 | -1 | -1 | 0 | 0 | |
| https://www.forbes.com/sites/matthewherper/ | 1 | 0.18 | 0.78 | 0.05 | -1 | - | -1 | -1 | -1 | -1 | 0 | 0 |
Hubs from forbes.com
Pages from domain with most likely on-topic outgoing links.
Similar domains to forbes.com
Similar domains to domain, based on inbound linking patterns from other relevant domains. This is also known in SEO as topical co-citation.